Cadrenal Therapeutics Rings the Closing Bell in Celebration of its IPO

About This Event

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Quang Pham, Chairman and CEO, rings the Closing Bell.

Nasdaq Originals Exclusive insights on the forces shaping the convergence of technology, business and sports. Explore